SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-20-019237
Filing Date
2020-09-02
Accepted
2020-09-02 17:04:27
Documents
10
Period of Report
2020-08-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20200901_8k.htm 8-K 37668
2 EXHIBIT 3.1 ex_202700.htm EX-3.1 7588
3 EXHIBIT 3.2 ex_202520.htm EX-3.2 98343
4 EXHIBIT 5.1 ex_202521.htm EX-5.1 17084
5 EXHIBIT 10.1 ex_202522.htm EX-10.1 90090
6 EXHIBIT 10.2 ex_202523.htm EX-10.2 164587
7 f2.jpg GRAPHIC 2401
8 footer.jpg GRAPHIC 8199
9 h2.jpg GRAPHIC 4329
10 header.jpg GRAPHIC 7547
  Complete submission text file 0001437749-20-019237.txt   448075
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 201157523
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences